Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649
1. Text Correction
2. Error in Table 1
Reference
- König, C.; Both, A.; Rohde, H.; Kluge, S.; Frey, O.R.; Röhr, A.C.; Wichmann, D. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649. [Google Scholar] [CrossRef] [PubMed]
Case | Sex | Age [Years] | Weight [kg] | CKD-EPI eGFR (mL/min/1.72 m2) or Mode of Renal Replacement Therapy | Cefiderocol Dose [mg/24 h] | Cefiderocol Through Level [mg/L] | Focus of Infection | SOFA/SAPS | Medical History | Outcome Related to the Event | Pathogen Isolated | MIC [mg/L] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Available Isolate | Last Available Isolate | ||||||||||||
1 | m | 41 | 75 | CVVHD DFR 2.0 L/min * | 2000 | 25.2 (day 4) | CAP | 11/49 | PAH; interstitial lung disease; chronic renal impairment | CC + MC | P. aeruginosa | 0.5 | 0.25 |
CVVHD DFR 2.0 L/min * | 2000 | 32.0 (day 5) | |||||||||||
2 | f | 69 | 60 | 67 | 3000 | 70 (day 3) | HAP | 4/33 | Esophagectomy, IPA, mediastinitis | MC | P. aeruginosa | 0.25 | n. a. |
22 | 2000 | 49 (day 7) | |||||||||||
3 | m | 76 | 85 | 84 | 6000 | 36.8 (day 1) | HAP; Primary Sepsis | 9/49 | COVID-19; ARDS, ECMO | MC | A. baumannii | 0.25 | 0.25 |
85 | 6000 | 43.2 (day 3) | |||||||||||
81 | 6000 | 59.5 (day 4) | |||||||||||
4 | m | 53 | 60 | 28 CVVHD DFR 2.4 L/min* | 6000 3000 | 42 (day 1) >100 (day 3) | Primary Sepsis | 14/68 | ASCT; GvHD c/I; invasive mold infection; HHV-6 encephalitis; BKV-cystitis | died | P. aeruginosa | 0.125 | 16 |
5 | m | 50 | 90 | CVVHD DFR 2.4 L/min * + CytoSorb® ** | 6000 | 26 (day 1) 13 (day 2) | HAP | 19/59 | COVID-19; ARDS, ECMO | died | A. baumannii | 0.25 | n.a. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
König, C.; Both, A.; Rohde, H.; Kluge, S.; Frey, O.R.; Röhr, A.C.; Wichmann, D. Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649. Antibiotics 2021, 10, 1230. https://doi.org/10.3390/antibiotics10101230
König C, Both A, Rohde H, Kluge S, Frey OR, Röhr AC, Wichmann D. Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649. Antibiotics. 2021; 10(10):1230. https://doi.org/10.3390/antibiotics10101230
Chicago/Turabian StyleKönig, Christina, Anna Both, Holger Rohde, Stefan Kluge, Otto R. Frey, Anka C. Röhr, and Dominic Wichmann. 2021. "Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649" Antibiotics 10, no. 10: 1230. https://doi.org/10.3390/antibiotics10101230